Oxford Nanopore are sponsoring, exhibiting and presenting at this event.
The Oxford Nanopore Satellite symposium will take place on Friday 17th November at 07:15 - 08:15.
The session, chaired by Justin O'Grady, Senior Director, Translational Applications, will highlight the role of the Oxford Nanopore Technologies Drug-Resistant TB sequencing test in the rapid characterisation of drug resistance profiles directly from decontaminated sputum samples in diverse global settings.
Please check below for full speaker details and register to join the satellite session.
Please visit us at Booth #3330 if you are able to attend the event.
The Dream Fund project on nanopore sequencing for tuberculosis and other infectious diseases in low- and middle-income countries; first experiences from Kyrgyzstan
Kristin Kremer, Team Lead Diagnostics , KNCV Tuberculosis Foundation
Use of Nanopore Sequencing on Stool to Diagnose and Determine Drug Susceptibility of Tuberculosis
Tara Ness, Pediatric Infectious Diseases Fellow , Baylor of Medicine/Texas Children’s Hospital
Streamlining of TB drug susceptibility testing of M. tuberculosis by integration of the BD MAX MDR-TB real-time PCR assay with NanoTB® (Oxford Nanopore Technologies) targeted next generation sequencing
Uladzimir Antonenka , Program Manager , Institute of Microbiology and Laboratory Medicine, WHO Supranational Reference Laboratory for Tuberculosis